<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Psychogeriatr</journal-id><journal-id journal-id-type="iso-abbrev">Int Psychogeriatr</journal-id><journal-id journal-id-type="publisher-id">IPG</journal-id><journal-title-group><journal-title>International Psychogeriatrics</journal-title></journal-title-group><issn pub-type="ppub">1041-6102</issn><issn pub-type="epub">1741-203X</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28780910</article-id><article-id pub-id-type="pmc">5647675</article-id><article-id pub-id-type="doi">10.1017/S1041610217001442</article-id><article-id pub-id-type="pii">S1041610217001442</article-id><article-id pub-id-type="publisher-id">00144</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Drug-related problems in community-dwelling primary care patients screened
positive for dementia</article-title><alt-title alt-title-type="left-running">D. Wucherer <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Drug-related problems in dementia</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9324-1043</contrib-id><name><surname>Wucherer</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor001"/></contrib><contrib contrib-type="author"><name><surname>Thyrian</surname><given-names>J. R.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eichler</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hertel</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kilimann</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Michalowsky</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zwingmann</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dreier-Wolfgramm</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ritter</surname><given-names>C. A.</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Teipel</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hoffmann</surname><given-names>W.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>German Center for Neurodegenerative Diseases
(DZNE)</addr-line>, <institution>Rostock/Greifswald</institution>,
<addr-line>Greifswald</addr-line>, <country>Germany</country></aff><aff id="aff002"><label>2</label><addr-line>Department of Psychiatry and
Psychotherapy</addr-line>, <institution>University Medicine Greifswald</institution>,
<addr-line>Greifswald</addr-line>, <country>Germany</country></aff><aff id="aff003"><label>3</label><addr-line>German Center for Neurodegenerative Diseases
(DZNE)</addr-line>, <institution>Rostock/Greifswald</institution>,
<addr-line>Rostock</addr-line>, <country>Germany</country></aff><aff id="aff004"><label>4</label><addr-line>Department of Psychosomatic Medicine</addr-line>,
<institution>Rostock University Medical Center</institution>,
<addr-line>Rostock</addr-line>, <country>Germany</country></aff><aff id="aff005"><label>5</label><addr-line>Institute for Community Medicine</addr-line>,
<addr-line>Section Epidemiology of Health Care and Community Health</addr-line>,
<institution>University Medicine Greifswald</institution>,
<addr-line>Greifswald</addr-line>, <country>Germany</country></aff><aff id="aff006"><label>6</label><addr-line>Institute of Pharmacy</addr-line>,
<addr-line>Section Clinical Pharmacy</addr-line>, <institution>University of
Greifswald</institution>, <addr-line>Greifswald</addr-line>, <country>Germany</country></aff><author-notes><corresp id="cor001"><italic>Correspondence should be addressed to</italic>: Diana Wucherer,
<institution>German Center for Neurodegenerative Diseases (DZNE)</institution>,
<addr-line>Rostock/Greifswald</addr-line>, <addr-line>Ellernholzstrasse 1&#x02013;2
17487</addr-line>, <addr-line>Greifswald</addr-line>, <country>Germany</country>. Phone:
<phone>+49 3834 86 7591</phone>; Fax: <fax>+49 383486 19551</fax>. Email: <email xlink:href="diana.wucherer@dzne.de">diana.wucherer@dzne.de</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>07</day><month>8</month><year>2017</year></pub-date><volume>29</volume><issue>11</issue><fpage>1857</fpage><lpage>1868</lpage><history><date date-type="received"><day>22</day><month>3</month><year>2017</year></date><date date-type="rev-request"><day>08</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>30</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; International Psychogeriatric Association 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>International Psychogeriatric Association</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted
re-use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S1041610217001442a.pdf"/><abstract abstract-type="normal"><sec><title>Background:</title><p>Older people have a higher risk of drug-related problems (DRPs). However, little is
known about the prevalence of DRPs in community-dwelling people who screened positive
for dementia. Our study aimed to determine (1) the prevalence and types of DRPs and (2)
the socio-demographic and clinical variables associated with DRPs in people screened
positive for dementia in primary care.</p></sec><sec><title>Methods:</title><p>The Dementia: life- and person-centered help in Mecklenburg-Western Pomerania
(DelpHi-MV) study is a general practitioner (GP)-based cluster-randomized controlled
intervention study to implement and evaluate an innovative concept of collaborative
dementia care management in the primary care setting in Germany. Medication reviews of
446 study participants were conducted by pharmacists based on a comprehensive baseline
assessment that included a computer-based home medication assessment. ClinicalTrials.gov
Identifier: NCT01401582.</p></sec><sec><title>Results:</title><p>A total of 1,077 DRPs were documented. In 414 study participants (93%), at least one
DRP was detected by a pharmacist. The most frequent DRPs were administration and
compliance problems (60%), drug interactions (17%), and problems with inappropriate drug
choice (15%). The number of DRPs was significantly associated with the total number of
drugs taken and with a formal diagnosis of a mental or behavioral disorder.</p></sec><sec><title>Conclusions:</title><p>Degree of cognitive impairment (MMSE defined) and formal diagnosis of dementia were not
risk factors for an increased number of DRPs. However, the total number of drug taken
and the presence of a diagnosis of mental and behavioral disorders were associated with
an increased total number of DRPs.</p></sec></abstract><kwd-group><title>Key words:</title><kwd>primary care</kwd><kwd>dementia</kwd><kwd>DelpHi-MV study</kwd><kwd>drug-related problem</kwd><kwd>medication review</kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><ref-count count="47"/><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Approximately 75% of the 1.5 million people with dementia (PwD) in Germany are
community-dwelling patients (Grass-Kapanke <italic>et al.</italic>, <xref rid="ref013" ref-type="bibr">2008</xref>). Most of them (up to 77%) are affected by multiple chronic
diseases and are treated with complex pharmacotherapy regimes (up to seven chronic-use drugs
per patient) that are associated with drug-related problems (DRPs) (Elliott <italic>et
al.</italic>, <xref rid="ref008" ref-type="bibr">2015</xref>; Gustafsson <italic>et
al.</italic>, <xref rid="ref015" ref-type="bibr">2016</xref>; Wucherer <italic>et
al.</italic>, <xref rid="ref045" ref-type="bibr">2016</xref>). The Pharmaceutical Care
Network Europe defines a DRP as &#x0201c;an event or circumstance involving drug therapy that
actually or potentially interferes with desired health outcomes&#x0201d; (Pharmaceutical Care
Network Europe Foundation, <xref rid="ref035" ref-type="bibr">2010</xref>). DRPs include
drug&#x02013;drug interactions, an over- or under-supply of medication, non-compliance, application
errors, inadequate self-medication, adverse drug reactions, and drug abuse. DRPs can lead to
increase in morbidity, reduction in quality of life, medication-related hospital admissions,
and higher healthcare costs (Leendertse <italic>et al.</italic>, <xref rid="ref028" ref-type="bibr">2011</xref>; Gustafsson <italic>et al.</italic>, <xref rid="ref015" ref-type="bibr">2016</xref>). Advanced age and impaired cognition increase the risk of DRPs;
a prospective multicenter study from the Netherlands identified impaired cognition as one of
the main determinants of preventable medication-related hospital admissions in the general
population (Leendertse <italic>et al.</italic>, <xref rid="ref027" ref-type="bibr">2008</xref>). To date, little is known about the association between dementia diseases and
the presence of DRPs in primary care. A high prevalence of DRPs in this population would
drive the inclusion of systematic medication reviews in dementia care programs. Identifying
risk factors for DRPs would help allocate medication review resources to the population at
the highest risk. Accordingly, the goals of the present analysis were to determine (1) the
frequency and the type of DRPs and (2) the socio-demographic and clinical variables
associated with DRPs in people who screened positive for dementia in a German
community-dwelling setting.</p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec2-1"><title>Study design and data collection</title><p>The present cross-sectional analysis was based on data from the Dementia: life- and
person-centered help in Mecklenburg-Western Pomerania (DelpHi-MV) study, a GP-based,
cluster-randomized, controlled intervention study to implement and evaluate an innovative
concept of collaborative dementia care management in Germany (ClinicalTrials.gov
Identifier: NCT01401582). More details about the DelpHi-MV study was published elsewhere
(Thyrian et al., <xref rid="ref042" ref-type="bibr">2012</xref>; Thyrian et al., <xref rid="ref043" ref-type="bibr">2016</xref>). The age of the patients was 70 years or
older; they lived at home, screened positively for dementia with DemTect (&#x0003c;9)
(Calabrese and Kessler, <xref rid="ref002" ref-type="bibr">2000</xref>) as an inclusion
criterion in participating GP practices, and provided a written informed consent for
participation in the study. If a patient was unable to give written informed consent, the
form was signed on his or her behalf by his or her legal representative (as approved by
the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania,
registry number BB 20/11). A comprehensive standardized baseline assessment was conducted
at the participant's home by study nurses with dementia-specific qualifications and
included a computer-assisted home medication assessment. Detailed description of home
medication assessment in DelpHi-MV study was published by Fiss et al. (<xref rid="ref010" ref-type="bibr">2013</xref>). The study nurses (<italic>n</italic> = 6)
were trained by the study pharmacists (<italic>n</italic> = 2) to perform the medication
assessment. The structured training included information about the principles of drug
administration, pharmacotherapy for older patients, and DRPs. For the computer-assisted
home medication assessment, the study nurses also judged medication storage, timeliness of
the medication list, necessity of the pill dispenser, and the abilities of the study
participants or caregivers to manage the medication by themselves.</p></sec><sec id="sec2-2"><title>Participants</title><p>A total of 6,838 patients was screened for dementia in 125 GP practices. Of these, 1,166
patients (17%) were eligible for the DelpHi-MV study, 634 patients (54%) agreed to
participate. One hundred and eighteen patients dropped out of the study before the
baseline assessment due to withdrawal of informed consent: <italic>n</italic> = 85, death:
<italic>n</italic> = 19, relocation: <italic>n</italic> = 5, or other reasons:
<italic>n</italic> = 9, and 516 participants started the baseline assessment. A total of
70 participants was excluded from the present analyses during the period of baseline
assessment due to the missing data (missing data: <italic>n</italic> = 46; death:
<italic>n</italic> = 2; withdrawal of the informed consent: <italic>n</italic> = 18;
moving away: <italic>n</italic> = 1; not assessed: <italic>n</italic> = 1; other reasons:
<italic>n</italic> = 2). Accordingly, the present analysis was based on the data of 446
participants of the DelpHi-MV study with a complete baseline medication review.</p><p>There were no significant differences in age, sex, or the DemTect score among patients
included in the analysis (<italic>n</italic> = 516) and those who dropped out of the study
before baseline assessment (<italic>n</italic> = 118) (see Table S1 available as
supplementary material online attached to the electronic version of this paper at <uri xlink:type="simple" xlink:href="http://journals.cambridge.org/ipg">http://journals.cambridge.org/ipg</uri>). Furthermore, no significant differences were
observed in age, sex, or DRPs between the analyzed patients and those who were excluded
because of missing data in any covariate included in the analyses. However, patients
excluded from the analyses due to missing data showed lower DemTect scores compared to
patients included in the analyses (DemTect score 6.1 (SD = 1.90) vs. 4.5 (SD = 2.08),
<italic>p</italic> = 0.001) (see Table S2 available as supplementary material online
attached to the electronic version of this paper at <uri xlink:type="simple" xlink:href="http://journals.cambridge.org/ipg">http://journals.cambridge.org/ipg</uri>).</p></sec><sec id="sec2-3"><title>Data analyses</title><p>A total of 371 (83.2%) medication reviews for our analysis was conducted by the study
pharmacists (<italic>n</italic> = 2), and 75 (16.8%) medication reviews were conducted by
pharmacists from the study's participating public pharmacies. All pharmacists prepared the
medication review independently and identified existing and potential DRPs. The study
pharmacists (<italic>n</italic> = 2) trained the pharmacists (<italic>n</italic> = 37) in
the study's participating public pharmacies (<italic>n</italic> = 29). The structured
training included the following aspects: pharmacotherapy for older patients, special cases
of pharmacotherapy in dementia diseases, DRPs, DelpHi-MV study structure, implementation
of medication review, and special features of documentation. The training materials were
given to the pharmacists in the form of a portfolio; the pharmacists also had the ability
to consult the study pharmacist by phone.</p><p>The home medication assessment examined the study participant's entire medication history
(prescription drugs and over-the-counter (OTC) drugs) including compliance, adverse
effects, and drug administration (Fiss <italic>et al.</italic>, <xref rid="ref010" ref-type="bibr">2013</xref>). A community pharmacist or the pharmacist in the study center
conducted the medication review for the study's participants. Active substances were coded
according to the Anatomical Therapeutic Chemical (ATC) classification system (WIdO
(Wissenschaftliches Institut der AOK), <xref rid="ref044" ref-type="bibr">2016</xref>).
Topical agents and homeopathic medicines were not considered in this analysis. The DRPs
were grouped into five main groups according to the PIE-Doc&#x000ae;-System (Schaefer, <xref rid="ref040" ref-type="bibr">2002</xref>): inappropriate drug choice; inappropriate
administration by patients/problems with administration and compliance; inappropriate
dosage/problems with the dosage; problems with drug interactions; and problems with
adverse drug events (ADEs). Drug interactions, drug&#x02013;food interactions, and double
prescriptions (of the same drugs or of the drugs in the same drug class) were identified
by the Risk-Check tool CAVE of the ABDA-Database. A &#x0201c;traffic light system,&#x0201d; a pragmatic
system of DDI classification of the ABDA-Database, was employed to classify the drug
interactions and drug&#x02013;food interactions into six categories of severity: &#x0201c;serious
consequences probable, contraindicated,&#x0201d; &#x0201c;contraindicated as a precaution,&#x0201d; &#x0201c;monitoring or
adjustment is needed,&#x0201d; &#x0201c;monitoring and adjustment is necessary in some cases,&#x0201d; &#x0201c;supervise
as a precaution,&#x0201d; and &#x0201c;no action is normally required&#x0201d; (Pharma-Daten-Service, <xref rid="ref036" ref-type="bibr">2017</xref>). The first three categories of severity were
considered during medication reviews. The clinical relevance of drug&#x02013;drug interactions was
assessed by the pharmacists during the medication review implementation. In the analysis,
the interactions of category &#x0201c;monitoring or adjustment is needed&#x0201d; were described as
&#x0201c;potential drug interactions of moderate severity.&#x0201d; The interactions of categories
&#x0201c;serious consequences probable, contraindicated&#x0201d; and &#x0201c;contraindicated as a precaution&#x0201d;
were summed as &#x0201c;potential drug interactions, clinically relevant.&#x0201d; Potentially
inappropriate medications (PIMs), the drugs for which the risk of an ADE outweighs the
clinical benefit, particularly when there is an evidence in favor of a safer or more
effective alternative therapy for the same condition (Laroche <italic>et al.</italic>,
<xref rid="ref023" ref-type="bibr">2009</xref>), were determined using a list of PIM in
the elderly (Priscus list). The German Priscus list was established in line with the
international PIM lists and published in 2010, aiming to reduce the rate of ADE and to
provide higher medication safety (Holt <italic>et al.</italic>, <xref rid="ref018" ref-type="bibr">2010</xref>).</p><p>To analyze the associations between DRPs and socio-demographic and clinical variables,
the following variables were considered: age, sex, support with medication (yes/no),
cognitive status, functional status, depressive symptoms, visit to a specialist
(neurologist/psychiatrist (yes/no)), total number of drugs taken, formal diagnosis of
dementia, diagnosis of mental and behavioral disorders, and number of comorbid diagnoses.
The severity of cognitive impairment was evaluated using the Mini-Mental State Examination
(MMSE) (Kessler <italic>et al.</italic>, <xref rid="ref022" ref-type="bibr">1990</xref>).
The following categories for the severity were applied: &#x0201c;no indication of cognitive
impairment&#x0201d; (score 27&#x02013;30) and &#x0201c;mild&#x0201d; (20&#x02013;26), &#x0201c;moderate&#x0201d; (10&#x02013;19), or &#x0201c;severe&#x0201d; (0&#x02013;9)
cognitive impairment (Deutsche Gesellschaft f&#x000fc;r Psychiatrie und Psychotherapie,
Psychosomatik und Nervenheilkunde (DGPPN), <xref rid="ref003" ref-type="bibr">2016</xref>). The Geriatric Depression Scale (GDS) was used to assess depressive symptoms
which were categorized as dichotomized variable in two categories &#x0201c;no depression&#x0201d; (score
0&#x02013;5) and &#x0201c;possible depression&#x0201d; (score 6&#x02013;15) (Gauggel and Birkner, <xref rid="ref012" ref-type="bibr">1999</xref>). The functional status was assessed using the Bayer Activities
of Daily Living Scale (B-ADL) (Hindmarch <italic>et al.</italic>, <xref rid="ref017" ref-type="bibr">1998</xref>) with a mean score between 1 and 10, where 1 indicates the
lowest and 10 indicates the highest possible impairment. According to the International
Classification of Diseases and Related Health Problems (ICD-10, German Modification)
(Deutsches Institut f&#x000fc;r medizinische Dokumentation und Information (DIMDI), <xref rid="ref004" ref-type="bibr">2011</xref>), medical diagnoses were retrieved from the
participants&#x02019; medical records of an individual patient's GP. A dementia diagnosis refers
to any of the following ICD-10 codes: F00/G30 (dementia due to Alzheimer's disease), F01
(vascular dementia), F02 (dementia in other diseases), F03 (unspecified dementia), or G31
(other degenerative diseases of nervous system, not otherwise classified). Diagnosis of
mental and behavioral disorders refers to the ICD-10 codes F04-F69.</p></sec><sec id="sec2-4"><title>Statistical analyses</title><p>We fitted Poisson regression models to evaluate which variables were associated with the
total number of DRPs. The regression model included the degree of cognitive impairment
(MMSE defined) as an explanatory variable. Age, sex, living situation (dichotomous: living
alone or not alone), functional status (measured with Bayer-ADL), depressive symptoms
(measured with GDS), total number of drug taken, documented diagnosis of dementia before
screening (dichotomous: having a dementia diagnosis or not), the number of somatic
comorbidities (as total number from the medical records), and diagnosis of mental and
behavioral disorders (dichotomous: having a diagnosis or not) were included as covariates.
Whereas socio-demographic factors and the total number of drugs taken were included to
attenuate possible confounding factors, the clinical variables were the predictors of
interest. To account for the clustering of participants who were recruited by the same GP,
we included random effects of the GP in the Poisson regression model. For sensitivity
analyses, we ran a mixed effect negative binomial regression with the same specifications.
Before running the final regression model, we checked for non-linear relations using the
multivariate fractional polynomial procedure (Royston and Sauerbrei, <xref rid="ref039" ref-type="bibr">2008</xref>). However, we found no indication of non-linear relationships.
Furthermore, by using exploratory analyses, we checked the associations of the same
predictors with problems (dichotomous: prevalent vs. not prevalent) in single categories
with analogous logistic regressions. All regression analyses were performed in the
remaining 446 cases belonging to 90 clusters (unequal sample sizes per cluster). The
standard errors of the regression coefficients were estimated using the jackknife
technique, which provides appropriate estimates of standard errors in complex samples
(Efron and Tibshirani, <xref rid="ref006" ref-type="bibr">1986</xref>). Statistical
analyses were performed using STATA&#x000ae;13 (StataCorp, <xref rid="ref041" ref-type="bibr">2014</xref>).</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Socio-demographic and clinical characteristics of the study sample</title><p>The socio-demographic and clinical characteristics of the study sample for this analysis
are represented in <xref ref-type="table" rid="tbl001">Table 1</xref>. More detailed
characteristics of the whole study sample have been published by Thyrian <italic>et
al.</italic> (<xref rid="ref043" ref-type="bibr">2016</xref>). <table-wrap id="tbl001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Socio-demographic and clinical characteristics of study sample</p></caption><alternatives><graphic xlink:href="S1041610217001442_tab1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">
<sc>community-dwelling people screened</sc>
</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">
<sc>positive for dementia:</sc>
</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<sc>total</sc>
</th><th align="left" rowspan="1" colspan="1">
<sc>without DRP</sc>
</th><th align="left" rowspan="1" colspan="1">
<sc>with DRP</sc>
</th><th align="left" rowspan="1" colspan="1">
<italic>t</italic>
</th><th align="left" rowspan="1" colspan="1">
<sc>df</sc>
</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic>n</italic> = 446</td><td align="left" rowspan="1" colspan="1"><italic>n</italic> = 31</td><td align="left" rowspan="1" colspan="1"><italic>n</italic> = 415</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age, mean (SD)</td><td rowspan="1" colspan="1">79.8(5.4)</td><td rowspan="1" colspan="1">81.2(6.9)</td><td rowspan="1" colspan="1">79.7(5.3)</td><td rowspan="1" colspan="1">1.184</td><td rowspan="1" colspan="1">32.906</td><td rowspan="1" colspan="1">0.244<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Sex (female), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">257(57.6)</td><td rowspan="1" colspan="1">17(54.8)</td><td rowspan="1" colspan="1">240(57.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.851<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Degree of cognitive impairment (MMSE defined), mean
(SD)</td><td rowspan="1" colspan="1">22.5(5.0)</td><td rowspan="1" colspan="1">21.0(4.7)</td><td rowspan="1" colspan="1">22.7(5.0)</td><td rowspan="1" colspan="1">&#x02212;1.848</td><td rowspan="1" colspan="1">35.686</td><td rowspan="1" colspan="1">0.073<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">No cognitive impairment (score, 27&#x02013;30)</td><td rowspan="1" colspan="1">106(23.8)</td><td rowspan="1" colspan="1">4(12.9)</td><td rowspan="1" colspan="1">102(24.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mild cognitive impairment (score, 20&#x02013;26)</td><td rowspan="1" colspan="1">235(52.7)</td><td rowspan="1" colspan="1">16(51.6)</td><td rowspan="1" colspan="1">219(52.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Moderate cognitive impairment (score, 10&#x02013;19)</td><td rowspan="1" colspan="1">96(21.5)</td><td rowspan="1" colspan="1">11(35.5)</td><td rowspan="1" colspan="1">85(20.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Severe cognitive impairment (score, 0&#x02013;9)</td><td rowspan="1" colspan="1">9(2.0)</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">9(2.2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.184<sup>b*</sup></td></tr><tr><td rowspan="1" colspan="1">Formal diagnosis of dementia (ICD-10:
F00-F03/G30/G31) (yes), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">166(37.2)</td><td rowspan="1" colspan="1">13(41.9)</td><td rowspan="1" colspan="1">153(36.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.569<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Diagnosis of mental and behavioral disorders
(ICD-10: F04-F69) (yes), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">116(25.9)</td><td rowspan="1" colspan="1">6(19.3)</td><td rowspan="1" colspan="1">110(26.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.628<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Previous visit to specialist
(neurologist/psychiatrist), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">115(25.8)</td><td rowspan="1" colspan="1">5(16.1)</td><td rowspan="1" colspan="1">110(26.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.287<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Support with medication (yes), <italic>n</italic>
(%)</td><td rowspan="1" colspan="1">93(20.9)</td><td rowspan="1" colspan="1">6(19.4)</td><td rowspan="1" colspan="1">87(21.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.000<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Comorbid diagnoses, mean (SD)</td><td rowspan="1" colspan="1">12.1(7.3)</td><td rowspan="1" colspan="1">10.8(5.7)</td><td rowspan="1" colspan="1">12.2(7.4)</td><td rowspan="1" colspan="1">&#x02212;1.310</td><td rowspan="1" colspan="1">38.519</td><td rowspan="1" colspan="1">0.198<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">Total no. of drugs, mean (SD)</td><td rowspan="1" colspan="1">6.4(3.2)</td><td rowspan="1" colspan="1">4.4(2.9)</td><td rowspan="1" colspan="1">6.6(3.2)</td><td rowspan="1" colspan="1">&#x02212;4.015</td><td rowspan="1" colspan="1">35.860</td><td rowspan="1" colspan="1">
<bold>0.001<sup>a</sup></bold>
</td></tr><tr><td rowspan="1" colspan="1">Living alone (yes), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">220(49.3)</td><td rowspan="1" colspan="1">14(45.2)</td><td rowspan="1" colspan="1">206(49.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.711<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Depression (GDS) (yes), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">72(16.1)</td><td rowspan="1" colspan="1">3(9.7)</td><td rowspan="1" colspan="1">69(16.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.448<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Functional status (B-ADL), mean (SD)</td><td rowspan="1" colspan="1">3.6(2.4)</td><td rowspan="1" colspan="1">4.0(2.7)</td><td rowspan="1" colspan="1">3.6(2.4)</td><td rowspan="1" colspan="1">0.905</td><td rowspan="1" colspan="1">33.932</td><td rowspan="1" colspan="1">0.371<sup>a</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab1-tfn001"><p>Standard deviations or percentages are in brackets. MMSE, Mini-Mental State
Examination (range 0&#x02013;30; higher score indicates better cognitive functioning);
B-ADL, Bayer Activities of Daily Living Scale (range 0&#x02013;10; lower score indicates
better performance); GDS, Geriatric Depression Scale (sum score 0&#x02013;15; score &#x02265;6
indicates depression); <sup>a</sup>Welch's <italic>t</italic>-test,
<sup>b</sup>Fisher's exact test; *Fisher's exact test calculation for all
MMSE-categories; bold <italic>p</italic>-value indicates <italic>p</italic>
&#x0003c; 0.05; df, degrees of freedom; <italic>t</italic>,
<italic>t</italic>-statistic of the Welch's <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-2"><title>Drug-related problems</title><p>Polypharmacy, defined here as the use of five or more prescription medications that was
to be taken according to a fixed schedule (none &#x0201c;<italic>pro re nata</italic>&#x0201d;
medication), was identified in 67.3% (<italic>n</italic> = 300) of the study participants.
Of the 446 total patients, a 414 (92.8%) had at least one DRP (<xref ref-type="fig" rid="fig001">Figure 1</xref>) detected by a pharmacist (in the community pharmacies or
in the study center) or a study nurse during a home visit. Almost two-thirds of the study
participants (<italic>n</italic> = 286/446; 64.1%) had one to three detected DRPs, and
almost one-third of the study participants (<italic>n</italic> = 122/446; 27.3%) had four
to seven DRPs. Six study participants (1.4%) had eight to twelve DRPs. The mean time
required for the medication review of each patient was about 25 minutes (SD = 18 minutes).
<fig id="fig001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Prevalence of drug-related problems in the study samples (percentages may not sum
to 100, because of rounding).</p></caption><graphic xlink:href="S1041610217001442_fig1"/></fig></p><p>A total of 1,077 DRPs were registered. Problems related to administration and compliance
were the most common group of DRPs (59.9% of registered DRPs; <italic>n</italic> = 645),
followed by problems with drug interactions (16.7%; <italic>n</italic> = 180), problems
with inappropriate drug choice (14.7%; <italic>n</italic> = 158), problems with the dosage
(6.2%; <italic>n</italic> = 67), and problems with ADEs (2.5%; <italic>n</italic> = 27).
The most frequent specific DRPs included the following problems: inadequate drug storage
(195 of 446 study participants; 43.7% of all study participants in our analysis),
inappropriate time of application (<italic>n</italic> = 180/446; 40.4%), inappropriate
combination of drugs (<italic>n</italic> = 155/446; 34.8%), no medication list/medication
list outdated (<italic>n</italic> = 110/446; 24.7%), inappropriate drugs according to the
Priscus list (<italic>n</italic> = 105/446; 22.9%), and forgetting to take the drug
(<italic>n</italic> = 82/446; 18.4%) (<xref ref-type="table" rid="tbl002">Table
2</xref>). Two percent of the study participants (<italic>n</italic> = 9) took
cholinesterase inhibitors and anticholinergic drugs (quetiapine: <italic>n</italic> = 5
cases; amitriptyline: <italic>n</italic> = 3; doxepin, <italic>n</italic> = 1;
tolterodine, <italic>n</italic> = 1) at the same time. <table-wrap id="tbl002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Distribution of drug-related problems, according to the PIE-Doc&#x000ae;-System</p></caption><alternatives><graphic xlink:href="S1041610217001442_tab2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<sc>study participants</sc>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
<sc>main group of DRPs</sc>
</th><th align="left" rowspan="1" colspan="1">
<sc>specific DRPs</sc>
</th><th align="left" rowspan="1" colspan="1">
<sc>with DRP</sc>
<xref ref-type="fn" rid="tab2-tfn001">
<sup>1</sup>
</xref>
<sc>No</sc>
<xref ref-type="fn" rid="tab2-tfn002">
<sup>2</sup>
</xref>
<sc>. (%)</sc>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">Contraindication</td><td rowspan="1" colspan="1">3 (0.7)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Double prescription of active ingredient</td><td rowspan="1" colspan="1">16 (3.6)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Double prescription of therapeutic group</td><td rowspan="1" colspan="1">13 (2.9)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate drug form</td><td rowspan="1" colspan="1">15 (3.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate drug according to Priscus list</td><td rowspan="1" colspan="1">102 (22.9)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Untreated indication</td><td rowspan="1" colspan="1">9 (2.0)</td></tr><tr><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">Inappropriate duration of application: too long</td><td rowspan="1" colspan="1">22 (4.9)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate duration of application: too short</td><td rowspan="1" colspan="1">2 (0.5)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate time of application</td><td rowspan="1" colspan="1">180 (40.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No intake due to forgetfulness</td><td rowspan="1" colspan="1">82 (18.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Multiple drug taking</td><td rowspan="1" colspan="1">22 (4.9)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Not drug use by physical complaints</td><td rowspan="1" colspan="1">6 (1.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Self-omission of the drug by the patient</td><td rowspan="1" colspan="1">23 (5.2)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inadequate storage</td><td rowspan="1" colspan="1">184 (41.3)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inadequate storage in refrigerator</td><td rowspan="1" colspan="1">11 (2.5)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No medication list/medication list is outdated</td><td rowspan="1" colspan="1">110 (24.7)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Use beyond expiration date</td><td rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Lack of knowledge on correct application</td><td rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">Drug dose too high</td><td rowspan="1" colspan="1">36 (8.1)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate timing of dosing intervals</td><td rowspan="1" colspan="1">10 (2.2)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage increase with good tolerability recommendable</td><td rowspan="1" colspan="1">21 (4. 7)</td></tr><tr><td rowspan="1" colspan="1">Drug interactions</td><td rowspan="1" colspan="1">Potential drug interactions of moderate severity</td><td rowspan="1" colspan="1">155 (34.8)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Potential drug interactions, clinically relevant</td><td rowspan="1" colspan="1">14 (3.1)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Inappropriate combination of drugs with food</td><td rowspan="1" colspan="1">11 (2.5)</td></tr><tr><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">27 (6.1)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab2-tfn001"><label>1</label><p>Duplicate entry was possible.</p></fn><fn id="tab2-tfn002"><label>2</label><p>One case of DRP was defined as the occurrence of the problem in a study
participant. The case with drug&#x02013;drug interactions means, for example, that a study
participant has the drug&#x02013;drug interactions, regardless of the number of
interactions.</p></fn></table-wrap-foot></table-wrap></p><p>The comparison the rate and classification of DRPs detected by the study pharmacists
versus the trained public pharmacists showed only one significant difference, the public
pharmacists registered more DDIs. For DDI detection in both cases, one and the same
database (ABDA) was used, the public pharmacists have recorded more DDI with lower
severity.</p></sec><sec id="sec3-3"><title>Factors associated with drug-related problems</title><p>The results of the multivariate logistic regression analyses (<italic>n</italic> = 446
study participants assigned to <italic>n</italic> = 90 clusters) are shown in <xref ref-type="table" rid="tbl003">Tables 3</xref> and <xref ref-type="table" rid="tbl004">4</xref>. The results of the multivariate logistic regression analysis for different main
groups of DRPs (<xref ref-type="table" rid="tbl003">Table 3</xref>) revealed that degree
of cognitive impairment (MMSE defined) was associated with ADEs reported by the study
participants (OR: 1.20; 95% CI: 1.06&#x02013;1.36; <italic>p</italic> = 0.004). The total number
of drugs taken (OR: 1.26; 95% CI: 1.15&#x02013;1.39; <italic>p</italic> &#x0003c; 0.001) and
support with medication (OR: 1.78; 95% CI: 1.05&#x02013;3.02; <italic>p</italic> = 0.033) were
associated with drug interactions. The presence of a diagnosis of mental and behavioral
disorders was associated with problems of inappropriate drug choice (OR: 1.66; 95% CI:
1.24&#x02013;2.21; <italic>p</italic> = 0.001; significant regression model for problems with
inappropriate drug choice: <italic>&#x003c7;</italic><sup>2</sup>(10) = 33.30, <italic>p</italic>
&#x0003c; 0.001; problems with ADEs: <italic>&#x003c7;</italic><sup>2</sup>(10) = 19.38,
<italic>p</italic> = 0.036; problems with interactions: <italic>&#x003c7;</italic><sup>2</sup>(10)
= 56.15, <italic>p</italic> &#x0003c; 0.001). <table-wrap id="tbl003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Factors associated with main groups of DRPs</p></caption><alternatives><graphic xlink:href="S1041610217001442_tab3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><sc>main group of</sc> DRPs</th><th align="left" rowspan="1" colspan="1">OR</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="left" rowspan="1" colspan="1">95%</th><th align="left" rowspan="1" colspan="1">CI</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.16</td><td rowspan="1" colspan="1">0.527</td><td rowspan="1" colspan="1">0.72</td><td rowspan="1" colspan="1">1.89</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.21</td><td rowspan="1" colspan="1">0.505</td><td rowspan="1" colspan="1">0.70</td><td rowspan="1" colspan="1">2.09</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">0.63</td><td rowspan="1" colspan="1">0.182</td><td rowspan="1" colspan="1">0.32</td><td rowspan="1" colspan="1">1.25</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">0.71</td><td rowspan="1" colspan="1">0.459</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">1.74</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">0.488</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">1.35</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">0.766</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">1.05</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">0.177</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">1.04</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">0.071</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">1.01</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">0.136</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">1.16</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.524</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">1.03</td></tr><tr><td rowspan="1" colspan="1">Functional status (B-ADL)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">0.280</td><td rowspan="1" colspan="1">0.84</td><td rowspan="1" colspan="1">1.05</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">0.92</td><td rowspan="1" colspan="1">0.177</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">1.04</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">0.375</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">1.25</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.21</td><td rowspan="1" colspan="1">
<bold>0.049</bold>
</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.47</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.791</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">1.10</td></tr><tr><td rowspan="1" colspan="1">Degree of Cognitive Impairment (MMSE defined)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.776</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.06</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.02</td><td rowspan="1" colspan="1">0.570</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">1.08</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.447</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.11</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.20</td><td rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">1.36</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.795</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">1.08</td></tr><tr><td rowspan="1" colspan="1">Total number of drugs</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.16</td><td rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">1.26</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.456</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.13</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">0.216</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">1.18</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.13</td><td rowspan="1" colspan="1">0.063</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">1.29</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td rowspan="1" colspan="1">1.21</td><td rowspan="1" colspan="1">1.43</td></tr><tr><td rowspan="1" colspan="1">Depression (GDS) (yes)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.74</td><td rowspan="1" colspan="1">0.068</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">3.16</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.30</td><td rowspan="1" colspan="1">0.484</td><td rowspan="1" colspan="1">0.63</td><td rowspan="1" colspan="1">2.67</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">0.82</td><td rowspan="1" colspan="1">0.657</td><td rowspan="1" colspan="1">0.34</td><td rowspan="1" colspan="1">1.98</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.54</td><td rowspan="1" colspan="1">0.427</td><td rowspan="1" colspan="1">0.53</td><td rowspan="1" colspan="1">4.42</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">0.840</td><td rowspan="1" colspan="1">0.58</td><td rowspan="1" colspan="1">1.93</td></tr><tr><td rowspan="1" colspan="1">Formal diagnosis of dementia (ICD-10:
F00-F03/G30/G31) (yes)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">0.506</td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">1.38</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">0.87</td><td rowspan="1" colspan="1">0.615</td><td rowspan="1" colspan="1">0.50</td><td rowspan="1" colspan="1">1.50</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.43</td><td rowspan="1" colspan="1">0.294</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">2.79</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">0.65</td><td rowspan="1" colspan="1">0.382</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">1.72</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.29</td><td rowspan="1" colspan="1">0.281</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">2.07</td></tr><tr><td rowspan="1" colspan="1">Support with medication (yes)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">0.85</td><td rowspan="1" colspan="1">0.583</td><td rowspan="1" colspan="1">0.48</td><td rowspan="1" colspan="1">1.50</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">
<bold>0.019</bold>
</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.71</td><td rowspan="1" colspan="1">0.158</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">3.63</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">0.42</td><td rowspan="1" colspan="1">0.187</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">1.52</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.78</td><td rowspan="1" colspan="1">
<bold>0.033</bold>
</td><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">3.02</td></tr><tr><td rowspan="1" colspan="1">Total number of comorbid diagnoses</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.283</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.01</td><td rowspan="1" colspan="1">0.607</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">1.06</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">0.255</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">1.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.546</td><td rowspan="1" colspan="1">0.92</td><td rowspan="1" colspan="1">1.05</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.750</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">1.03</td></tr><tr><td rowspan="1" colspan="1">Diagnosis of mental and behavioral disorders
(ICD-10: F04-F69) (yes)</td><td rowspan="1" colspan="1">Inappropriate drug choice</td><td rowspan="1" colspan="1">1.66</td><td rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td rowspan="1" colspan="1">1.24</td><td rowspan="1" colspan="1">2.21</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Administration and compliance</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">0.677</td><td rowspan="1" colspan="1">0.75</td><td rowspan="1" colspan="1">1.56</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Dosage</td><td rowspan="1" colspan="1">1.59</td><td rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td rowspan="1" colspan="1">1.15</td><td rowspan="1" colspan="1">2.21</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adverse drug events</td><td rowspan="1" colspan="1">1.30</td><td rowspan="1" colspan="1">0.332</td><td rowspan="1" colspan="1">0.76</td><td rowspan="1" colspan="1">2.22</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interactions</td><td rowspan="1" colspan="1">1.25</td><td rowspan="1" colspan="1">0.113</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.63</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab3-tfn001"><p>Multivariate logistic regression analysis (446 participants assigned to 90
clusters) with GP as random effect variable. For each main group of DRP, there
exists LR-<italic>&#x003c7;</italic><sup>2</sup> and <italic>p</italic>: Problems with
inappropriate drug choice: <italic>&#x003c7;</italic><sup>2</sup>(10) = 33.30,
<italic>p</italic> &#x0003c; 0.001; Problems with administration and compliance:
<italic>&#x003c7;</italic><sup>2</sup>(10) = 16.56, <italic>p</italic> &#x0003c; 0.085;
Problems with dosage: <italic>&#x003c7;</italic><sup>2</sup>(10) = 17.39,
<italic>p</italic> &#x0003c; 0.066; Problems with adverse drug events:
<italic>&#x003c7;</italic><sup>2</sup>(10) = 19.38, <italic>p</italic> = 0.036; Problems
with interactions: <italic>&#x003c7;</italic><sup>2</sup>(10) = 56.15, <italic>p</italic>
&#x0003c; 0.001. Data presented as mean &#x000b1;standard deviation or <italic>n</italic>
(%). OR, odds ratio; CI, confidence interval; MMSE, Mini-Mental State Examination
(range 0&#x02013;30; higher score indicates better cognitive functioning); B-ADL, Bayer
Activities of Daily Living Scale (range 0&#x02013;10; lower score indicates better
performance); GDS, Geriatric Depression Scale (sum score 0&#x02013;15; score &#x02265;6 indicates
depression); bold <italic>p</italic>-values indicate <italic>p</italic> &#x0003c;
0.05.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tbl004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Factors associated with total number of DRPs</p></caption><alternatives><graphic xlink:href="S1041610217001442_tab4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<sc>bootstrap</sc>
</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>b</italic>
</th><th align="center" rowspan="1" colspan="1">
<sc>Std. Err.</sc>
</th><th align="center" rowspan="1" colspan="1">
<italic>z</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" colspan="2" rowspan="1">
<sc>95% CI</sc>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">&#x02212;0.002</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#x02212;0.37</td><td rowspan="1" colspan="1">0.709</td><td rowspan="1" colspan="1">&#x02212;0.02</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">1.20</td><td rowspan="1" colspan="1">0.233</td><td rowspan="1" colspan="1">&#x02212;0.05</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">Cognitive impairment (MMSE)</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">1.38</td><td rowspan="1" colspan="1">0.170</td><td rowspan="1" colspan="1">&#x02212;0.00</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">Functional status (B-ADL)</td><td rowspan="1" colspan="1">&#x02212;0.005</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">&#x02212;0.34</td><td rowspan="1" colspan="1">0.738</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">Depression (GDS) (yes)</td><td rowspan="1" colspan="1">0.13</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">1.52</td><td rowspan="1" colspan="1">0.131</td><td rowspan="1" colspan="1">&#x02212;0.04</td><td rowspan="1" colspan="1">0.31</td></tr><tr><td rowspan="1" colspan="1">Total no. of drugs</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">6.62</td><td rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">Support with medication</td><td rowspan="1" colspan="1">&#x02212;0.09</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">&#x02212;0.97</td><td rowspan="1" colspan="1">0.336</td><td rowspan="1" colspan="1">&#x02212;0.29</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">Comorbid diagnoses</td><td rowspan="1" colspan="1">&#x02212;0.001</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#x02212;0.29</td><td rowspan="1" colspan="1">0.772</td><td rowspan="1" colspan="1">&#x02212;0.01</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">Diagnosis of mental and behavioral disorders
(ICD-10: F04-F69) (yes)</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">3.06</td><td rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Living alone (yes)</td><td rowspan="1" colspan="1">&#x02212;0.03</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02212;0.50</td><td rowspan="1" colspan="1">0.616</td><td rowspan="1" colspan="1">&#x02212;0.17</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1">Diagnosis of dementia (ICD-10: F00-F03/G30/G31)
(yes)</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">0.31</td><td rowspan="1" colspan="1">0.757</td><td rowspan="1" colspan="1">&#x02212;0.11</td><td rowspan="1" colspan="1">0.15</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tab4-tfn001"><p>Multivariate Poisson regression analysis (446 participants assigned to 90
clusters) with GP as random effect variable: <italic>F</italic>(11.89) = 6.72,
<italic>p</italic> &#x0003c; 0.001. Confidence intervals were estimated via the
jackknife procedure. CI, confidence interval; MMSE, Mini-Mental State Examination;
B-ADL, Bayer Activities of Daily Living Scale; GDS, Geriatric Depression Scale;
bold <italic>p</italic>-values indicate <italic>p</italic> &#x0003c; 0.05;
<italic>z</italic>, <italic>z</italic>-statistic (derived by dividing the
regression coefficient by its standard error).</p></fn></table-wrap-foot></table-wrap></p><p>In the multivariate Poisson regression analysis, the total number of drugs taken
(<italic>b</italic> = 0.07; 95% CI: 0.05&#x02013;0.09; <italic>p</italic> &#x0003c; 0.001) and
the presence of a diagnosis of mental and behavioral disorders (<italic>b</italic> = 0.09;
95% CI: 0.03&#x02013;0.15; <italic>p</italic> = 0.003) were associated with total number of DRPs
(significant regression model: <italic>F</italic>(11,89) = 6.18, <italic>p</italic>
&#x0003c; 0.001; see <xref ref-type="table" rid="tbl004">Table 4</xref>). Cognitive
impairment was not associated with the total number of DRPs. The multivariate negative
binomial regression analysis provided similar results (see Table S3 availabled as
supplementary material online attached to the electronic version of this paper at <uri xlink:type="simple" xlink:href="http://journals.cambridge.org/ipg">http://journals.cambridge.org/ipg</uri>).</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>We reported the prevalence and correlates of DRPs in a large sample of community-dwelling
primary care patients in Germany who screened positive for dementia. In our setting, 93% of
the study participants had at least one DRP. Our findings are in line with a Swedish
randomized controlled clinical trial assessing patients aged &#x02265;75 years living in nursing
homes or the community and receiving municipal healthcare. They reported the same DRP
prevalence of 93% for 182 patients (a mean of 2.5 DRPs per patient, SD 1.5) as in our study
(Milos <italic>et al.</italic>, <xref rid="ref031" ref-type="bibr">2013</xref>). Our results
for the polypharmacy subgroup (67% of the DelpHi-MV study participants with five or more
prescription medications) are comparable to the 95% prevalence of at least one DRP observed
in a recent analysis of participants from senior centers and residential facilities in the
USA aged 60 years and older (mean age 75.9 &#x000b1; 8.5) taking five or more medications (O'Connell
<italic>et al.</italic>, <xref rid="ref033" ref-type="bibr">2015</xref>). A high number of
drugs taken increase the number of DRPs in persons both with dementia and without dementia,
as has been shown in previous studies (Lau <italic>et al.</italic>, <xref rid="ref024" ref-type="bibr">2010</xref>; Kaufmann <italic>et al.</italic>, <xref rid="ref021" ref-type="bibr">2015</xref>; Lavan and Gallagher, <xref rid="ref026" ref-type="bibr">2016</xref>). The majority of the study participants (67%) in our analysis were patients
with polypharmacy, this prevalence rate is higher compared to the prevalence in geriatric
ambulatory care population in Germany (27%) (Junius-Walker <italic>et al.</italic>, <xref rid="ref020" ref-type="bibr">2007</xref>) and worldwide (29%&#x02013;59%) (Fialova <italic>et
al.</italic>, <xref rid="ref009" ref-type="bibr">2005</xref>; Lau <italic>et al.</italic>,
<xref rid="ref024" ref-type="bibr">2010</xref>). Our findings fall in the upper range of
prevalence rates found in previous studies of community-dwelling older adults with dementia
(45%&#x02013;73%) (Lau <italic>et al.</italic>, <xref rid="ref025" ref-type="bibr">2011</xref>;
Oesterhus <italic>et al.</italic>, <xref rid="ref034" ref-type="bibr">2016</xref>). The
results of the multivariate regression analysis confirmed a strong association of the total
number of drugs taken with the occurrence of DRPs.</p><sec id="sec4-1"><title>Problems caused by administration and compliance</title><p>The majority of DRPs were related to administration and compliance (59% of all detected
DRPs). Some of these DRPs (inadequate storage, multiple drug taking, or no medication
list) can only be found by visiting patients&#x02019; home. We found that 41% of the study
participants stored their medication inadequately. Thus, medication was exposed to
moisture or light or was scattered around the house and, hence, poorly traceable. Critical
was the inadequate storage of medications in refrigerators, which occurred by 2.5% of the
study participants. This included both the medications that did not need the refrigeration
and the refrigerated medications stored outside the refrigerator. Importantly, 1.6% of the
study participants with insulin-dependent diabetes stored their insulin outside a
refrigerator. The inappropriate storage of medication was most common in patients with
polypharmacy. Our findings strongly support the notion that home-based medication review
is required to amend a high number of administration- and compliance-related drug
problems. In our cohort, 18% of the participants reported in the structured interview that
they &#x0201c;often&#x0201d; forget to take their medications; 5% of the participants indicated that they
took their medication more often than necessary. This is in line with the results by
Elliott where 14% of elderly Australian patients admitted to regularly forgetting to take
medication (Elliott, <xref rid="ref007" ref-type="bibr">2006</xref>). Adherence is
difficult to detect objectively even by a home visit and is underreported (DiMatteo, <xref rid="ref005" ref-type="bibr">2004</xref>). The recent systematic review of seven
European and U.S. studies revealed that the prevalence of non-adherence in elderly
patients living at home ranged from 6% to 55%, and was associated with poor cognition and
higher number of drugs taken (Zelko <italic>et al.</italic>, <xref rid="ref046" ref-type="bibr">2016</xref>). The same review indicated that there are problems with tools
used for the assessment of adherence. We found that inappropriate timing of drug
applications occurred in 40% of the study's participants. The term &#x0201c;Incorrect timing of
application&#x0201d; in our analysis included both the time of day and the relation to food (with
breakfast, an empty stomach, etc.). Incorrect timing of applications was identified in
those drugs for which the correct time of intake is important for safety and efficacy of
the therapy (e.g. alendronate, levothyroxine, acetylsalicylic acid, and statins). In this
analysis, 25% of study participants had no medication list or the medication list was
outdated according to the assessment of the study nurse. We cannot estimate if this rate
of PwD is high or low because in German studies, the rate of elderly patients with
polypharmacy who do not have a medication list differs greatly between 10% and 75% (J&#x000e4;ger
<italic>et al.</italic>, <xref rid="ref019" ref-type="bibr">2017</xref>). Nevertheless,
these findings are relevant because the study participants took six prescribed drugs on
average. The absence of a medication list could contribute to a high number of problems
caused by administration and compliance in our study sample.</p></sec><sec id="sec4-2"><title>Problems with drug interactions</title><p>In our analysis, problems with potential drug interactions were the second most common
category (17% of all detected DRPs), which reflects the high number of drugs taken &#x02013; on
average, each participant took 6.4 prescribed drugs chronically. Accordingly, the total
number of drugs was significantly associated with drug interactions in the multivariate
analysis. Furthermore, support with medication intake from a caregiver or professional
care service was significantly associated with more drug interactions. Our interpretation
of this finding is that support for medication intake is more frequent in people with
diseases that are treated with medications with high interaction potential. More than
one-third (35%) of the DelpHi-MV study participants used at least one drug combination
that could potentially lead to a drug interaction of moderate severity. This is in line
with the results by Oesterhus <italic>et al.</italic> where 36% of community-dwelling
people with mild dementia in Norway (Oesterhus <italic>et al.</italic>, <xref rid="ref034" ref-type="bibr">2016</xref>) had drug interactions. Another analysis with
the elderly general population in six European countries showed a higher proportion of
drug interactions: 46% of the patients had at least one potential drug interaction
(Bj&#x000f6;rkman <italic>et al.</italic>, <xref rid="ref001" ref-type="bibr">2002</xref>). With
increasing number of diseases to treat, the likelihood of drug interaction must be weighed
against the necessity to treat a given disease. The information about drug interactions
should be used for careful monitoring in this vulnerable population, and for the planned
reduction of polypharmacy. In this analysis, a potential clinically relevant drug
interaction was detected in 3% of the study participants; this rate is slightly higher
than the results of Oesterhus <italic>et al.</italic> (less as 2%) (Oesterhus <italic>et
al.</italic>, <xref rid="ref034" ref-type="bibr">2016</xref>).</p><p>We found that 2% of the study participants took cholinesterase inhibitors and
anticholinergic drugs at the same time. Antidementia drugs should not be co-administrated
with anticholinergic drugs due to the risk of the effect elimination. Physicians should
avoid this combination, and PwD and their caregivers should be sensitized for the use of
drugs with anticholinergic properties.</p></sec><sec id="sec4-3"><title>Problems with inappropriate drug choice</title><p>The most common problems with inappropriate drug choice were PIMs according to the
Priscus list (23% of study participants received at least one PIM) and the double
prescription of active agents (7% of study participants). The prescription rate of PIMs
was comparable to the rates found in the general elderly population in Germany (20%&#x02013;29%)
(Zimmermann <italic>et al.</italic>, <xref rid="ref047" ref-type="bibr">2013</xref>). The
most frequently prescribed PIMs were antidepressants, benzodiazepines, and analgesics. The
prevalence of double prescriptions in previous studies varies by setting and method.
Community pharmacists detected a lower prevalence of double prescriptions in the German
general population (approximately 2% of the patients visiting pharmacies) (Nicolas
<italic>et al.</italic>, <xref rid="ref032" ref-type="bibr">2013</xref>). Based on an
Austria's prescription data set a study reported that up to 15% of the patients receive
double prescriptions by different prescribers (Heinze <italic>et al.</italic>, <xref rid="ref016" ref-type="bibr">2016</xref>) and 25% to 40% percent of community-dwelling
older Australians are prescribed at least one PIM (Elliott, <xref rid="ref007" ref-type="bibr">2006</xref>). The diagnosis of mental and behavioral disorders was
significantly associated with problems of inappropriate drug choice. This can be explained
by the fact that many psychopharmaceuticals which are used to treat mental and behavioral
disorders are included in the PIM lists.</p></sec><sec id="sec4-4"><title>Problems with the dosage</title><p>In this analysis, for 8% of the patients, the dosage of drugs was too high according to
the current recommendations and guidelines. This prevalence might be overestimated,
because a high dosage (beyond the recommendations of the guidelines) could be
therapeutically justified. In 5% of participants, the medication review provided evidence
that the dosage may be too low. This was particularly the case for antidementia drugs,
such as cholinesterase inhibitors and memantine. However, final judgment of these numbers
is not possible since the medication review had no information on the tolerance of
antidementia drugs for the individual patient which may have been clinically justified.
The effective doses of antidementia drugs are known (16&#x02013;24 mg/24 hours of galantamine, 10
mg/24 hours of donepezil, 6&#x02013;12 mg/24 hours of rivastigmine or 9.5 mg/24 hours of
rivastigmine patch, 20 mg/hours of memantine). The assessment of dosage is an important
part of a comprehensive medication review to identify the inappropriate dosing.</p></sec><sec id="sec4-5"><title>Problems with adverse drug events</title><p>In our analysis, 6% of the study participants reported ADEs related to a prescribed
medication. This finding is in line with a previous study of Gurwitz <italic>et
al.</italic>, who reported a 5% frequency of ADEs in a population of outpatients aged 60
years and older (Gurwitz <italic>et al.</italic>, <xref rid="ref014" ref-type="bibr">2003</xref>). The proportion of outpatients with at least one ADE ranged from 5% to 35%
in previous studies (Gandhi <italic>et al.</italic>, <xref rid="ref011" ref-type="bibr">2003</xref>; Roughead <italic>et al.</italic>, <xref rid="ref038" ref-type="bibr">2004</xref>; Elliott, <xref rid="ref007" ref-type="bibr">2006</xref>), our results were
in the lower range. The number of self-reported ADEs in our analysis can be underestimated
because patients with moderate and severe cognitive impairment (22% and 2% of participants
in our study, respectively) more frequently had difficulties in communicating their ADEs
(Maidment <italic>et al.</italic>, <xref rid="ref030" ref-type="bibr">2008</xref>). This
assumption was supported by the results of our multivariate logistic regression analysis
for different groups of DRPs, results show that the study participants who had better
cognitive status reported ADEs more frequently. The validity of self-reported ADE's during
the home medication assessment is problematic. It is also possible that some ADEs were not
recognized or documented by the study nurses. The recent Australian study showed, that 16%
of hospitalized population had a confirmed ADE, half the ADEs were detected after the
patient had been admitted and the most were detected by the medical practitioners
(Phillips <italic>et al.</italic>, <xref rid="ref037" ref-type="bibr">2014</xref>). In our
analysis, the lack of GP evaluations of ADEs should be taken into account in the
interpretation of the results.</p></sec><sec id="sec4-6"><title>Limitations</title><p>The number of DRPs may be underrepresented in our analysis if the pharmacists did not
detect all possible DRPs. Another limitation is the study's dependence on self-reported
medication administration and ADEs. There was no additional monitoring of drug
administration or comparison of self-reported ADEs with the physician records; thus, our
results may underestimate the actual numbers. Patients who were excluded from the analyses
due to missing data had more severe cognitive impairment than did the patients who were
included. Accordingly, the present study included mostly patients with mild dementia and
only a few patients with severe dementia. Effects of severe dementia on DRPs might be
underrepresented.</p></sec></sec><sec sec-type="conclusions" id="sec5"><title>Conclusion</title><p>Our results confirm a high prevalence of DRPs in community-dwelling primary care patients
who screened positive for dementia. Cognitive impairment was not a risk factor for an
increased number of DRPs. However, the presence of a diagnosis of mental and behavioral
disorders was associated with an increased total number of DRPs. In line with earlier
studies, our study showed, that a high number of drugs taken is associated with an increased
number of DRPs (Lau <italic>et al.</italic>, <xref rid="ref024" ref-type="bibr">2010</xref>;
Maher <italic>et al.</italic>, <xref rid="ref029" ref-type="bibr">2014</xref>; Kaufmann
<italic>et al.</italic>, <xref rid="ref021" ref-type="bibr">2015</xref>; Oesterhus
<italic>et al.</italic>, <xref rid="ref034" ref-type="bibr">2016</xref>). Home medication
assessment by trained nurses provides benefits for patients with dementia and complex
medication regimens, because it gives comprehensive information on the actual medications
taken, including OTC drugs, nutritional factors, medication storage, having no or an
outdated medication list, no intake due to forgetfulness, multiple drug taking, and
self-omission of the drug by the patient. It reflects the real home medication situation
more than just checking a medication list at the doctor's office or at the pharmacy. Our
data suggest that it cannot be taken for granted that a prescribed drug is taken at the
right dosage by the right person and at the right time. Consistent with a range of previous
studies, we support comprehensive medication review in PwD and complex medication regimens
as part of routine care to avoid harm to patients and to reduce the costs incurred by DRPs
in healthcare systems worldwide.</p></sec><sec id="sec6"><title>Conflict of interest</title><p>None.</p></sec><sec id="sec7"><title>Description of authors&#x02019; roles</title><p>D. Wucherer supervised the data collection and drafted the paper. D. Wucherer, I. Kilimann,
C. A. Ritter, and S. Teipel were responsible for pharmaceutical analysis. T. Eichler
assisted with writing the paper, I. Zwingmann, A. Dreier-Wolfgramm, and B. Michalowsky
contributed to the paper in their fields of expertise. J. Hertel and S. Richter were
responsible for the statistical analyses. J.&#x000a0;R. Thyrian is the coordinator of the study and
contributed to the overall design. W. Hoffmann is the principal investigator of the study
and has contributed substantially to the concept of this study. All authors have read and
approved the final version of the paper.</p></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>The present analysis is part of the DelpHi-MV (Dementia: life- and person-centered help in
Mecklenburg-Western Pomerania) study and was performed in cooperation of the German Center
of Neurodegenerative Diseases (DZNE), University Medicine Greifswald, and University
Medicine Rostock. We would like to thank all study participants, their caregivers, general
practitioners, and pharmacists for the excellent cooperation.</p></ack><sec sec-type="supplementary-material" id="sec8"><title>Supplementary material</title><supplementary-material content-type="local-data" id="S1041610217001442sup001"><p>For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S1041610217001442.</p><media xlink:href="S1041610217001442sup001.zip" mimetype="application" mime-subtype="zip" orientation="portrait" id="d35e2674" position="anchor"><caption><p>click here to view supplementary material</p></caption></media></supplementary-material></sec><ref-list id="REFa"><title>References</title><ref id="ref001"><mixed-citation publication-type="journal"><name><surname>Bj&#x000f6;rkman</surname><given-names>I. K.</given-names></name>, <name><surname>Fastbom</surname><given-names>J.</given-names></name>, <string-name>
<surname>Schmidt</surname>
</string-name>, <string-name>
<given-names>I. K.</given-names>
<surname>Bernsten</surname>
</string-name>, <string-name>
<given-names>C. B.</given-names>
</string-name> and <collab>Pharmaceutical Care of the Elderly in Europe Research (PEER)
Group</collab> (<year>2002</year>). <article-title>Drug&#x02013;drug interactions in the
elderly</article-title>. <source>The Annals of Pharmacotherapy</source>,
<volume>36</volume>, <fpage>1675</fpage>&#x02013;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">12398558</pub-id></mixed-citation></ref><ref id="ref002"><mixed-citation publication-type="journal"><name><surname>Calabrese</surname><given-names>P.</given-names></name> and <name><surname>Kessler</surname><given-names>J.</given-names></name> (<year>2000</year>). <article-title>Screening for cognitive impairment in dementia
&#x02013; the DemTect procedure</article-title>. <source>European
Neuropsychopharmacology</source>, <volume>10</volume>,
<fpage>369</fpage>.</mixed-citation></ref><ref id="ref003"><mixed-citation publication-type="other"><collab>Deutsche Gesellschaft f&#x000fc;r Psychiatrie und
Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN)</collab> (<year>2016</year>).
<italic>S3-Leitlinie &#x0201c;Demenzen&#x0201d;</italic> Available at: <uri xlink:type="simple" xlink:href="http://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/038013_LL_Demenzen_2016.pdf">http://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/038013_LL_Demenzen_2016.pdf</uri>;
last accessed 9 December 2016.</mixed-citation></ref><ref id="ref004"><mixed-citation publication-type="other"><collab>Deutsches Institut f&#x000fc;r medizinische
Dokumentation und Information (DIMDI)</collab> (<year>2011</year>). <italic>ICD-10-GM
Version 2012 - Kapitel V</italic> Available at: <uri xlink:type="simple" xlink:href="https://www.dimdi.de/static/de/klassi/icd-10-gm/kodesuche/onlinefassungen/htmlgm2012/">https://www.dimdi.de/static/de/klassi/icd-10-gm/kodesuche/onlinefassungen/htmlgm2012/</uri>;
last accessed 11 December 2016.</mixed-citation></ref><ref id="ref005"><mixed-citation publication-type="journal"><name><surname>DiMatteo</surname><given-names>M. R.</given-names></name> (<year>2004</year>). <article-title>Variations in patients&#x02019; adherence to medical
recommendations: a quantitative review of 50 years of research</article-title>.
<source>Medical Care</source>, <volume>42</volume>,
<fpage>200</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">15076819</pub-id></mixed-citation></ref><ref id="ref006"><mixed-citation publication-type="journal"><name><surname>Efron</surname><given-names>B.</given-names></name> and <name><surname>Tibshirani</surname><given-names>R.</given-names></name> (<year>1986</year>). <article-title>Boostrap measures for standard errors,
confidence intervals and other measures of statistical accuracy</article-title>.
<source>Statistical Science</source>, <volume>1</volume>,
<fpage>54</fpage>&#x02013;<lpage>75</lpage>.</mixed-citation></ref><ref id="ref007"><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>R. A.</given-names></name> (<year>2006</year>). <article-title>Problems with medication use in the elderly:
an Australian perspective</article-title>. <source>Journal of Pharmacy Practice and
Research</source>, <volume>36</volume>,
<fpage>58</fpage>&#x02013;<lpage>66</lpage>.</mixed-citation></ref><ref id="ref008"><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>R. A.</given-names></name>, <name><surname>Goeman</surname><given-names>D.</given-names></name>, <name><surname>Beanland</surname><given-names>C.</given-names></name> and <name><surname>Koch</surname><given-names>S.</given-names></name> (<year>2015</year>). <article-title>Ability of older people with dementia or
cognitive impairment to manage medicine regimens: a narrative review</article-title>.
<source>Current Clinical Pharmacology</source>, <volume>10</volume>,
<fpage>213</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">26265487</pub-id></mixed-citation></ref><ref id="ref009"><mixed-citation publication-type="journal"><name><surname>Fialova</surname><given-names>D.</given-names></name>
<etal>et al</etal> (<year>2005</year>). <article-title>Potentially inappropriate
medication use among elderly home care patients in Europe</article-title>.
<source>Journal of the American Medical Association</source>, <volume>293</volume>,
<fpage>1348</fpage>&#x02013;<lpage>1358</lpage>.<pub-id pub-id-type="pmid">15769968</pub-id></mixed-citation></ref><ref id="ref010"><mixed-citation publication-type="journal"><name><surname>Fiss</surname><given-names>T.</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>Medication management for people
with dementia in primary care: description of implementation in the DelpHi
study</article-title>. <source>BMC Geriatrics</source>, <volume>13</volume>,
<fpage>121</fpage>.<pub-id pub-id-type="pmid">24225205</pub-id></mixed-citation></ref><ref id="ref011"><mixed-citation publication-type="journal"><name><surname>Gandhi</surname><given-names>T. K.</given-names></name>
<etal>et al</etal> (<year>2003</year>). <article-title>Adverse drug events in ambulatory
care</article-title>. <source>The New England Journal of Medicine</source>,
<volume>348</volume>, <fpage>1556</fpage>&#x02013;<lpage>1564</lpage>.<pub-id pub-id-type="pmid">12700376</pub-id></mixed-citation></ref><ref id="ref012"><mixed-citation publication-type="journal"><name><surname>Gauggel</surname><given-names>S.</given-names></name> and <name><surname>Birkner</surname><given-names>B.</given-names></name> (<year>1999</year>). <article-title>Validity and reliability of a German version
of the Geriatric Depression Scale (GDS)</article-title>. <source>Zeitschrift f&#x000fc;r
Klinische Psychologie-Forschung und Praxis</source>, <volume>28</volume>,
<fpage>18</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="ref013"><mixed-citation publication-type="other"><name><surname>Grass-Kapanke</surname><given-names>B.</given-names></name>, <name><surname>Kunczik</surname><given-names>T.</given-names></name> and <name><surname>Gutzmann</surname><given-names>H.</given-names></name> (<year>2008</year>). <italic>Studie zur Demenzversorgung im ambulanten Sektor -
DIAS</italic> Available at: <uri xlink:type="simple" xlink:href="http://www.dggpp.de/documents/DIAS.pdf">http://www.dggpp.de/documents/DIAS.pdf</uri>; last accessed 11 March
2016.</mixed-citation></ref><ref id="ref014"><mixed-citation publication-type="journal"><name><surname>Gurwitz</surname><given-names>J. H.</given-names></name>
<etal>et al</etal> (<year>2003</year>). <article-title>Incidence and preventability of
adverse drug events among older persons in the ambulatory setting</article-title>.
<source>Journal of the American Medical Association</source>, <volume>289</volume>,
<fpage>1107</fpage>&#x02013;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">12622580</pub-id></mixed-citation></ref><ref id="ref015"><mixed-citation publication-type="journal"><name><surname>Gustafsson</surname><given-names>M.</given-names></name>, <name><surname>Sjolander</surname><given-names>M.</given-names></name>, <name><surname>Pfister</surname><given-names>B.</given-names></name>, <name><surname>Jonsson</surname><given-names>J.</given-names></name>, <name><surname>Schneede</surname><given-names>J.</given-names></name> and <name><surname>Lovheim</surname><given-names>H.</given-names></name> (<year>2016</year>). <article-title>Drug-related hospital admissions among old
people with dementia</article-title>. <source>European Journal of Clinical
Pharmacology</source>, <volume>72</volume>,
<fpage>1143</fpage>&#x02013;<lpage>1153</lpage>.<pub-id pub-id-type="pmid">27377393</pub-id></mixed-citation></ref><ref id="ref016"><mixed-citation publication-type="journal"><name><surname>Heinze</surname><given-names>G.</given-names></name>
<etal>et al</etal> (<year>2016</year>). <article-title>Prevalence and determinants of
unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs
in Austria: a nationwide cohort study</article-title>. <source>Pharmacoepidemiology and
Drug Safety</source>, <volume>25</volume>,
<fpage>90</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">26468002</pub-id></mixed-citation></ref><ref id="ref017"><mixed-citation publication-type="journal"><name><surname>Hindmarch</surname><given-names>I.</given-names></name>, <name><surname>Lehfeld</surname><given-names>H.</given-names></name>, <name><surname>de Jongh</surname><given-names>P.</given-names></name> and <name><surname>Erzigkeit</surname><given-names>H.</given-names></name> (<year>1998</year>). <article-title>The bayer activities of daily living scale
(B-ADL)</article-title>. <source>Dementia and Geriatric Cognitive Disorders</source>,
<volume>9</volume>, <fpage>20</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="ref018"><mixed-citation publication-type="journal"><name><surname>Holt</surname><given-names>S.</given-names></name>, <name><surname>Schmiedl</surname><given-names>S.</given-names></name> and <name><surname>Thurmann</surname><given-names>P. A.</given-names></name> (<year>2010</year>). <article-title>Potentially inappropriate medications in the
elderly: the PRISCUS list</article-title>. <source>Deutsches &#x000c4;rzteblatt
International</source>, <volume>107</volume>,
<fpage>543</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">20827352</pub-id></mixed-citation></ref><ref id="ref019"><mixed-citation publication-type="journal"><name><surname>J&#x000e4;ger</surname><given-names>C.</given-names></name>
<etal>et al</etal> (<year>2017</year>). <article-title>Impact of a tailored program on
the implementation of evidence-based recommendations for multimorbid patients with
polypharmacy in primary care practices &#x02013; results of a cluster-randomized controlled
trial</article-title>. <source>Implementation Science</source>, <volume>12</volume>,
<fpage>8</fpage>.<pub-id pub-id-type="pmid">28086976</pub-id></mixed-citation></ref><ref id="ref020"><mixed-citation publication-type="journal"><name><surname>Junius-Walker</surname><given-names>U.</given-names></name>, <name><surname>Theile</surname><given-names>G.</given-names></name> and <name><surname>Hummers-Pradier</surname><given-names>E.</given-names></name> (<year>2007</year>). <article-title>Prevalence and predictors of polypharmacy
among older primary care patients in Germany</article-title>. <source>Family
Practice</source>, <volume>24</volume>,
<fpage>14</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">17164234</pub-id></mixed-citation></ref><ref id="ref021"><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>C. P.</given-names></name>, <name><surname>Stampfli</surname><given-names>D.</given-names></name>, <name><surname>Hersberger</surname><given-names>K. E.</given-names></name> and <name><surname>Lampert</surname><given-names>M. L.</given-names></name> (<year>2015</year>). <article-title>Determination of risk factors for drug-related
problems: a multidisciplinary triangulation process</article-title>. <source>BMJ
Open</source>, <volume>5</volume>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2014-006376</pub-id>.</mixed-citation></ref><ref id="ref022"><mixed-citation publication-type="other"><name><surname>Kessler</surname><given-names>J.</given-names></name>, <name><surname>Markowitsch</surname><given-names>H. J.</given-names></name> and <name><surname>Denzler</surname><given-names>P.</given-names></name> (<year>1990</year>). <italic>Mini-Mental-Status-Test (MMST) [German
Version]</italic> Available at: <uri xlink:type="simple" xlink:href="https://www.testzentrale.de/shop/mini-mental-status-test.html">https://www.testzentrale.de/shop/mini-mental-status-test.html</uri>;
last accessed 19 March 2015.</mixed-citation></ref><ref id="ref023"><mixed-citation publication-type="journal"><name><surname>Laroche</surname><given-names>M. L.</given-names></name>, <name><surname>Charmes</surname><given-names>J. P.</given-names></name>, <name><surname>Bouthier</surname><given-names>F.</given-names></name> and <name><surname>Merle</surname><given-names>L.</given-names></name> (<year>2009</year>). <article-title>Inappropriate medications in the
elderly</article-title>. <source>Clinical Pharmacology &#x00026; Therapeutics</source>,
<volume>85</volume>, <fpage>94</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">18987619</pub-id></mixed-citation></ref><ref id="ref024"><mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>D. T.</given-names></name>, <name><surname>Mercaldo</surname><given-names>N. D.</given-names></name>, <name><surname>Harris</surname><given-names>A. T.</given-names></name>, <name><surname>Trittschuh</surname><given-names>E.</given-names></name>, <name><surname>Shega</surname><given-names>J.</given-names></name> and <name><surname>Weintraub</surname><given-names>S.</given-names></name> (<year>2010</year>). <article-title>Polypharmacy and potentially inappropriate
medication use among community-dwelling elders with dementia</article-title>.
<source>Alzheimer Disease &#x00026; Associated Disorders</source>, <volume>24</volume>,
<fpage>56</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">19561441</pub-id></mixed-citation></ref><ref id="ref025"><mixed-citation publication-type="journal"><name><surname>Lau</surname><given-names>D. T.</given-names></name>, <name><surname>Mercaldo</surname><given-names>N. D.</given-names></name>, <name><surname>Shega</surname><given-names>J. W.</given-names></name>, <name><surname>Rademaker</surname><given-names>A.</given-names></name> and <name><surname>Weintraub</surname><given-names>S.</given-names></name> (<year>2011</year>). <article-title>Functional decline associated with
polypharmacy and potentially inappropriate medications in community-dwelling older
adults with dementia</article-title>. <source>American Journal of Alzheimer's Disease
&#x00026; Other Dementias</source>, <volume>26</volume>,
<fpage>606</fpage>&#x02013;<lpage>615</lpage>.</mixed-citation></ref><ref id="ref026"><mixed-citation publication-type="journal"><name><surname>Lavan</surname><given-names>A. H.</given-names></name> and <name><surname>Gallagher</surname><given-names>P.</given-names></name> (<year>2016</year>). <article-title>Predicting risk of adverse drug reactions in
older adults</article-title>. <source>Therapeutic Advances in Drug Safety</source>,
<volume>7</volume>, <fpage>11</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">26834959</pub-id></mixed-citation></ref><ref id="ref027"><mixed-citation publication-type="journal"><name><surname>Leendertse</surname><given-names>A. J.</given-names></name>, <name><surname>Egberts</surname><given-names>A. C.</given-names></name>, <name><surname>Stoker</surname><given-names>L. J.</given-names></name> and <name><surname>van den Bemt</surname><given-names>P. M.</given-names></name> (<year>2008</year>). <article-title>Frequency of and risk factors for preventable
medication-related hospital admissions in the Netherlands</article-title>.
<source>Archives of Internal Medicine</source>, <volume>168</volume>,
<fpage>1890</fpage>&#x02013;<lpage>1896</lpage>.<pub-id pub-id-type="pmid">18809816</pub-id></mixed-citation></ref><ref id="ref028"><mixed-citation publication-type="journal"><name><surname>Leendertse</surname><given-names>A. J.</given-names></name>, <name><surname>Van Den Bemt</surname><given-names>P. M.</given-names></name>, <name><surname>Poolman</surname><given-names>J. B.</given-names></name>, <name><surname>Stoker</surname><given-names>L. J.</given-names></name>, <name><surname>Egberts</surname><given-names>A. C.</given-names></name> and <name><surname>Postma</surname><given-names>M. J.</given-names></name> (<year>2011</year>). <article-title>Preventable hospital admissions related to
medication (HARM): cost analysis of the HARM study</article-title>. <source>Value in
Health</source>, <volume>14</volume>,
<fpage>34</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">21211484</pub-id></mixed-citation></ref><ref id="ref029"><mixed-citation publication-type="journal"><name><surname>Maher</surname><given-names>R. L.</given-names></name>, <name><surname>Hanlon</surname><given-names>J.</given-names></name> and <name><surname>Hajjar</surname><given-names>E. R.</given-names></name> (<year>2014</year>). <article-title>Clinical consequences of polypharmacy in
elderly</article-title>. <source>Expert Opinion on Drug Safety</source>,
<volume>13</volume>, <fpage>57</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">24073682</pub-id></mixed-citation></ref><ref id="ref030"><mixed-citation publication-type="journal"><name><surname>Maidment</surname><given-names>I. D.</given-names></name>, <name><surname>Haw</surname><given-names>C.</given-names></name>, <name><surname>Stubbs</surname><given-names>J.</given-names></name>, <name><surname>Fox</surname><given-names>C.</given-names></name>, <name><surname>Katona</surname><given-names>C.</given-names></name> and <name><surname>Franklin</surname><given-names>B. D.</given-names></name> (<year>2008</year>). <article-title>Medication errors in older people with mental
health problems: a review</article-title>. <source>International Journal of Geriatric
Psychiatry</source>, <volume>23</volume>,
<fpage>564</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">18058830</pub-id></mixed-citation></ref><ref id="ref031"><mixed-citation publication-type="journal"><name><surname>Milos</surname><given-names>V.</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>Improving the quality of
pharmacotherapy in elderly primary care patients through medication reviews: a
randomised controlled study</article-title>. <source>Drugs &#x00026; Aging</source>,
<volume>30</volume>, <fpage>235</fpage>&#x02013;<lpage>246</lpage>.<pub-id pub-id-type="pmid">23408163</pub-id></mixed-citation></ref><ref id="ref032"><mixed-citation publication-type="journal"><name><surname>Nicolas</surname><given-names>A.</given-names></name>, <name><surname>Eickhoff</surname><given-names>C.</given-names></name>, <name><surname>Griese</surname><given-names>N.</given-names></name> and <name><surname>Schulz</surname><given-names>M.</given-names></name> (<year>2013</year>). <article-title>Drug-related problems in prescribed medicines
in Germany at the time of dispensing</article-title>. <source>International Journal of
Clinical Pharmacy</source>, <volume>35</volume>,
<fpage>476</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">23605073</pub-id></mixed-citation></ref><ref id="ref033"><mixed-citation publication-type="journal"><name><surname>O'Connell</surname><given-names>M. B.</given-names></name>
<etal>et al</etal> (<year>2015</year>). <article-title>Drug-related-problem outcomes and
program satisfaction from a comprehensive brown bag medication review</article-title>.
<source>Journal of the American Geriatrics Society</source>, <volume>63</volume>,
<fpage>1900</fpage>&#x02013;<lpage>1905</lpage>.<pub-id pub-id-type="pmid">26313706</pub-id></mixed-citation></ref><ref id="ref034"><mixed-citation publication-type="journal"><name><surname>Oesterhus</surname><given-names>R.</given-names></name>, <name><surname>Aarsland</surname><given-names>D.</given-names></name>, <name><surname>Soennesyn</surname><given-names>H.</given-names></name>, <name><surname>Rongve</surname><given-names>A.</given-names></name>, <name><surname>Selbaek</surname><given-names>G.</given-names></name> and <name><surname>Kjosavik</surname><given-names>S. R.</given-names></name> (<year>2016</year>). <article-title>Potentially inappropriate medications and
drug&#x02013;drug interactions in home-dwelling people with mild dementia</article-title>.
<source>International Journal of Geriatric Psychiatry</source>, <volume>32</volume>,
<fpage>183</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">26924491</pub-id></mixed-citation></ref><ref id="ref035"><mixed-citation publication-type="other"><collab>Pharmaceutical Care Network Europe
Foundation</collab> (<year>2010</year>). <italic>The PCNE Classification V 6.2 -
Classification for Drug related problems</italic> Available at: <uri xlink:type="simple" xlink:href="http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf">http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf</uri>; last accessed 15
February 2016.</mixed-citation></ref><ref id="ref036"><mixed-citation publication-type="other"><collab>Pharma-Daten-Service</collab>
(<year>2017</year>). <italic>ABDA-Datenbank</italic> Available at: <uri xlink:type="simple" xlink:href="http://www.pharmazie.com/">http://www.pharmazie.com/</uri>; last accessed 15 February 2016.</mixed-citation></ref><ref id="ref037"><mixed-citation publication-type="journal"><name><surname>Phillips</surname><given-names>A. L.</given-names></name>
<etal>et al</etal> (<year>2014</year>). <article-title>Hospital admissions caused by
adverse drug events: an Australian prospective study</article-title>. <source>Australian
Health Review</source>, <volume>38</volume>,
<fpage>51</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">24351707</pub-id></mixed-citation></ref><ref id="ref038"><mixed-citation publication-type="journal"><name><surname>Roughead</surname><given-names>E. E.</given-names></name>, <name><surname>Barratt</surname><given-names>J. D.</given-names></name> and <name><surname>Gilbert</surname><given-names>A. L.</given-names></name> (<year>2004</year>). <article-title>Medication-related problems commonly occurring
in an Australian community setting</article-title>. <source>Pharmacoepidemiology and
Drug Safety</source>, <volume>13</volume>,
<fpage>83</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">14998069</pub-id></mixed-citation></ref><ref id="ref039"><mixed-citation publication-type="book"><name><surname>Royston</surname><given-names>P.</given-names></name> and <name><surname>Sauerbrei</surname><given-names>W.</given-names></name> (<year>2008</year>). <source>Multivariable Model-building &#x02013; A Pragmatic Approach
to Regression Analysis Based on Fractional Polynomials for Continuous
Variables</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley
&#x00026; Sons</publisher-name>.</mixed-citation></ref><ref id="ref040"><mixed-citation publication-type="journal"><name><surname>Schaefer</surname><given-names>M.</given-names></name> (<year>2002</year>). <article-title>Discussing basic principles for a coding
system of drug-related problems: the case of PI-Doc</article-title>. <source>Pharmacy
World &#x00026; Science</source>, <volume>24</volume>,
<fpage>120</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">12227243</pub-id></mixed-citation></ref><ref id="ref041"><mixed-citation publication-type="other"><collab>StataCorp</collab> (<year>2014</year>).
Stata Statistical Software: Release 13. In College Station, TX: StataCorp
LP.</mixed-citation></ref><ref id="ref042"><mixed-citation publication-type="journal"><name><surname>Thyrian</surname><given-names>J. R.</given-names></name>
<etal>et al</etal> (<year>2012</year>). <article-title>Life- and person-centred help in
Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised
controlled trial</article-title>. <source>Trials</source>, <volume>13</volume>,
<fpage>56</fpage>.<pub-id pub-id-type="pmid">22575023</pub-id></mixed-citation></ref><ref id="ref043"><mixed-citation publication-type="journal"><name><surname>Thyrian</surname><given-names>J. R.</given-names></name>
<etal>et al</etal> (<year>2016</year>). <article-title>Community-dwelling people screened
positive for dementia in primary care: a comprehensive, multivariate descriptive
analysis using data from the DelpHi-study</article-title>. <source>Journal of Alzheimers
Disease</source>, <volume>52</volume>,
<fpage>609</fpage>&#x02013;<lpage>617</lpage>.</mixed-citation></ref><ref id="ref044"><mixed-citation publication-type="other"><collab>WIdO (Wissenschaftliches Institut der
AOK)</collab> (<year>2016</year>). GKV-Arzneimittelindex. Available at: <uri xlink:type="simple" xlink:href="http://www.wido.de/amtl_atc-code.html">http://www.wido.de/amtl_atc-code.html</uri>; last accessed 15 February
2016.</mixed-citation></ref><ref id="ref045"><mixed-citation publication-type="journal"><name><surname>Wucherer</surname><given-names>D.</given-names></name>
<etal>et al</etal> (<year>2016</year>). <article-title>Potentially inappropriate
medication in community-dwelling primary care patients who were screened positive for
dementia</article-title>. <source>Journal of Alzheimers Disease</source>,
<volume>55</volume>, <fpage>691</fpage>&#x02013;<lpage>701</lpage>.</mixed-citation></ref><ref id="ref046"><mixed-citation publication-type="journal"><name><surname>Zelko</surname><given-names>E.</given-names></name>, <name><surname>Klemenc-Ketis</surname><given-names>Z.</given-names></name> and <name><surname>Tusek-Bunc</surname><given-names>K.</given-names></name> (<year>2016</year>). <article-title>Medication adherence in elderly with
polypharmacy living at home: a systematic review of existing studies</article-title>.
<source>Materia Socio-Medica</source>, <volume>28</volume>,
<fpage>129</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">27147920</pub-id></mixed-citation></ref><ref id="ref047"><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>T.</given-names></name>
<etal>et al</etal> (<year>2013</year>). <article-title>[Potentially inappropriate
medication in elderly primary care patients: a retrospective, longitudinal
analysis]</article-title>. <source>Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz</source>, <volume>56</volume>,
<fpage>941</fpage>&#x02013;<lpage>949</lpage>.<pub-id pub-id-type="pmid">23712323</pub-id></mixed-citation></ref></ref-list></back></article>